サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654722

臨床意思決定支援システムの世界市場：2025年～2033年

Global Clinical Decision Support System Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
臨床意思決定支援システムの世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

臨床意思決定支援システムの世界市場は、2024年に18億1,000万米ドルに達し、2033年までには33億4,000万米ドルに達すると予測され、予測期間の2025年から2033年のCAGRは7.4%で成長すると予測されています。

臨床意思決定支援システム（CDSS）は、臨床医、スタッフ、患者に合わせた知識や特定の情報を提供することで、ヘルスケアの提供を強化するように設計された高度な医療情報技術です。これらのシステムは、治療の時点における臨床上の意思決定を改善し、最終的に患者の転帰を向上させ、ヘルスケアプロセスを合理化することを目的としています。

CDSSは患者データを分析し、臨床知識と統合することで機能し、医療従事者が十分な情報に基づいた意思決定を行えるよう支援します。これには、効果的な診断と治療計画に不可欠な、タイムリーなアラート、リマインダー、エビデンスに基づく推奨事項の提供などが含まれます。これらのツールを活用することで、ヘルスケアプロバイダーは、質の高い患者ケアを提供するために不可欠な、適切な情報を適切なタイミングで入手することができます。このような要因が、世界の臨床意思決定支援システム市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

技術進歩の高まり

技術進歩の高まりは、臨床意思決定支援システム（CDSS）世界市場の重要な促進要因であり、ヘルスケアプロバイダーが臨床的意思決定にアプローチする方法を根本的に再構築しています。この変革は主に、人工知能（AI）、機械学習（ML）、ビッグデータ分析などの最先端技術のCDSSへの統合によるものです。

さらに、CDSSにAIを統合する業界の主要企業は、この市場の成長を促進すると思われます。例えば、Elsevier Healthは2024年2月、最先端の臨床意思決定支援ツールであるClinicalKey AIを発表しました。このツールは、信頼できる医療コンテンツと生成型人工知能（AI）を統合し、診療の時点で臨床医を支援します。この革新的なツールは、ヘルスケアテクノロジーの大きな進歩を意味し、臨床意思決定プロセスの改善に対するElsevierのコミットメントを強調するものです。

また、2023年2月には、Apollo HospitalsがClinical Intelligence Engine（CIE）を発表しました。これは、医師に高度な分析能力を持たせることで医療提供を強化するために設計された臨床意思決定支援システム（CDSS）です。これらすべての要因が、世界の臨床意思決定支援システム市場に需要をもたらしています。さらに、遠隔医療に対する需要の高まりも、世界の臨床意思決定支援システム市場の拡大に寄与しています。

データセキュリティとプライバシーに関する懸念

データセキュリティとプライバシーに関する懸念は、臨床意思決定支援システム（CDSS）の世界市場において重要な課題となっており、これらのシステムの採用と導入に影響を与えています。CDSSが患者の機密情報に広く依存していることを考えると、このデータの機密性と完全性を保護することは極めて重要です。

臨床意思決定支援システム（CDSS）の中には、既存の報告書作成ソフトや電子カルテ（EHR）ソフトとの相互運用性に欠けるスタンドアローン製品として運用されているものもあり、臨床と管理の両環境における有効性が制限されています。さらに、臨床研究や医療試験の発表が続いているため、CDSSは新しいデータを迅速に統合することが課題となっています。

病院のITエコシステムに統合された後でも、臨床判断支援システム（CDSS）は、ヘルスケア記録標準の多様性により、他のモジュールとの効果的な通信に苦労することがあります。幸いなことに、医療情報を交換・共有するための最新のHL7標準であるFast Healthcare Interoperability Resources（FHIR）の広範な採用により、この状況は改善されつつあります。従って、上記の要因が世界の臨床意思決定支援システム市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術進歩の高まり
    • 抑制要因
      • データセキュリティとプライバシーに関する懸念
    • 機会
    • 影響分析

第5章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー

第6章 製品別

  • 統合CDSS
  • スタンドアロンCDSS

第7章 タイプ別

  • 治療的CDSS
  • 診断用CDSS

第8章 コンポーネント別

  • サービス
  • ソフトウェア
  • ハードウェア

第9章 提供形態別

  • 病院・専門クリニック
  • 在宅医療
  • 外来手術センター
  • その他

第10章 エンドユーザー別

  • オンプレミス
  • ウェブベース
  • クラウドベース

第11章 モデル別

  • 知識ベースCDSS
  • 非知識ベースCDSS

第12章 アドバイス形態別

  • アクティブCDSS
  • パッシブCDSS

第13章 用途別

  • 薬物相互作用
  • 薬物アレルギー
  • 臨床上の注意
  • 臨床ガイドライン
  • 薬剤投与サポート
  • その他

第14章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター

第15章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第16章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第17章 企業プロファイル

  • Wolters Kluwer
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Oracle（Cerner Corporation）
  • Epic Systems Corporation.
  • McKesson Corporation
  • Veradigm Inc.（Allscripts Healthcare, LLC）
  • Elsevier
  • Optum, Inc
  • Siemens Healthcare Private Limited
  • Zynx Health, Inc.
  • Merative

第18章 付録

目次
Product Code: HCIT1700

The global clinical decision support system market reached US$ 1.81 billion in 2024 and is expected to reach US$ 3.34 billion by 2033, growing at a CAGR of 7.4 % during the forecast period 2025-2033.

Clinical decision support systems (CDSS) are sophisticated health information technologies designed to enhance the delivery of healthcare by providing clinicians, staff, and patients with tailored knowledge and specific information. These systems aim to improve clinical decision-making at the point of care, ultimately enhancing patient outcomes and streamlining healthcare processes.

CDSS functions by analyzing patient data and integrating it with clinical knowledge to assist healthcare professionals in making informed decisions. This includes delivering timely alerts, reminders, and evidence-based recommendations that are crucial for effective diagnosis and treatment planning. By leveraging these tools, healthcare providers can ensure that they have access to the right information at the right time, which is essential for delivering high-quality patient care. These factors have driven the global clinical decision support system market expansion.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

The rise in technological advancements is a crucial driver for the global clinical decision support system (CDSS) market, fundamentally reshaping how healthcare providers approach clinical decision-making. This transformation is primarily due to the integration of cutting-edge technologies such as artificial intelligence (AI), machine learning (ML), and big data analytics into CDSS.

Furthermore, key players in the industry integrating AI into CDSS would drive this market growth. For instance, in February 2024, Elsevier Health introduced ClinicalKey AI, a cutting-edge clinical decision support tool that integrates trusted medical content with generative artificial intelligence (AI) to assist clinicians at the point of care. This innovative tool signifies a major advancement in healthcare technology and underscores Elsevier's commitment to improving clinical decision-making processes.

Also, in February 2023, Apollo Hospitals recently introduced its Clinical Intelligence Engine (CIE), a Clinical Decision Support System (CDSS) designed to enhance healthcare delivery by equipping doctors with advanced analytical capabilities. All these factors demand the global clinical decision support system market. Moreover, the rising demand for the increasing demand for telemedicine contributes to the global clinical decision support system market expansion.

Data Security and Privacy Concerns

Data security and privacy concerns pose significant challenges in the global clinical decision support system (CDSS) market, affecting the adoption and implementation of these systems. Given that CDSS relies extensively on sensitive patient information, safeguarding the confidentiality and integrity of this data is crucial.

Some clinical decision support systems (CDSS) operate as standalone products that lack interoperability with existing reporting and Electronic Health Record (EHR) software, which limits their effectiveness in both clinical and administrative environments. Additionally, the ongoing publication of clinical research and medical trials creates challenges for CDSS in integrating new data promptly.

Even after being integrated into a hospital's IT ecosystem, clinical decision support systems (CDSS) can struggle to effectively communicate with other modules due to the diversity of healthcare record standards. Fortunately, this situation is improving with the broader adoption of Fast Healthcare Interoperability Resources (FHIR), the latest HL7 standard for exchanging and sharing healthcare information. Thus, the above factors could be limiting the global clinical decision support system market's potential growth.

Segment Analysis

The global clinical decision support system market is segmented based on product, type, component, delivery mode, model, mode of advice, application, end-user, and region.

Product:

The standalone CDSS segment is expected to dominate the global clinical decision support system market share

The standalone CDSS segment holds a major portion of the global clinical decision support system market share and is expected to continue to hold a significant portion of the global clinical decision support system market share during the forecast period.

Standalone clinical decision support systems (CDSS) play a significant role in the global clinical decision support systems market, characterized by their independent operation from other healthcare IT systems. While this independence offers specific advantages, it also presents disadvantages that influence their market position. Advantages of Standalone CDSS include it provides evidence-based recommendations, which can reduce errors and inconsistencies in clinical practice. Improves diagnostic accuracy, leading to more informed decisions and better assistance for physicians.Streamlines administrative tasks and offers diagnostic support, enhancing patient safety.

Standalone CDSS increased work efficiency leads to greater work efficiency, more personalized care, improved knowledge, increased confidence in decision-making, better prescribing behavior, and reduced unnecessary tests. Enables integrated workflows by providing assistance and care plan recommendations at the time of care.Lowers costs and increases efficiency by reducing unnecessary testing.Offers reminders for preventive care and alerts about potentially dangerous drug interactions.

Furthermore, key players in the industry research studies and innovative launches would drive this segment's growth in the global clinical decision support system market. For instance, according to the National Center for Biotechnology Information (NCBI) research study in June 2023, telemedicine and clinical decision support systems (CDSSs) play a crucial role in supporting patients with multimorbidity, which refers to the presence of multiple chronic conditions in a single individual. This demographic often faces complex healthcare challenges that can lead to a poor quality of life. Integrating CDSSs into telehealth services offers promising opportunities to enhance the quality and accessibility of care for these patients.

Also, in March 2024, Wolters Kluwer Health announced the launch of the next generation of its clinical decision support (CDS) solutions under the unified UpToDate portfolio. This new suite integrates various components of point-of-care decision support, workflow optimization, and patient-centered care resources into a cohesive and interoperable user experience. These factors have solidified the segment's position in the global clinical decision support system market.

Geographical Analysis

North America is expected to hold a significant position in the global clinical decision support system market share

North America holds a substantial position in the global clinical decision support system market and is expected to hold most of the market share. The increasing rates of chronic diseases, such as heart disease, stroke, cancer, and diabetes, are creating a greater need for CDSS to improve patient outcomes and manage complex conditions. Six in ten Americans had at least one chronic disease.

Supportive government initiatives and legislation, like the HITECH Act and the Meaningful Use program, are incentivizing the healthcare sector to implement health information technologies, including CDSS. North America's well-developed healthcare system, characterized by comprehensive EHR usage and effective health information exchange networks, facilitates the adoption and integration of CDSS.

Furthermore, in this region a major of key players presence, research activities, and innovative product launches would drive this global clinical decision support system market growth. For instance, in May 2024, a recent study by researchers at the Icahn School of Medicine at Mount Sinai demonstrated that generative AI models, such as GPT-4, can effectively predict hospital admissions for emergency room (ER) patients with limited training and data. The study, published in the Journal of the American Medical Informatics Association, analysed over 864,000 ER visits across seven Mount Sinai Health System hospitals, revealing that 18.5% of these visits resulted in hospital admissions. Researchers compared GPT-4's predictive capabilities against traditional machine learning models, including Bio-Clinical-BERT and XGBoost, and found that GPT-4 could improve clinical decision-making in high-pressure medical settings.

Also, in March 2024, Zynx Health launched Zynx for Primary Care, an innovative clinical decision support solution tailored specifically for primary care settings. This new offering aims to address the unique challenges faced by primary care teams, including chief medical information officers, providers, and informaticists, by enhancing provider satisfaction and streamlining workflows to reduce physician burnout. Thus, the above factors are consolidating the region's position as a dominant force in the global clinical decision support system market.

Asia Pacific is growing at the fastest pace in the global clinical decision support system market share

Asia Pacific holds the fastest pace in the global clinical decision support system market and is expected to hold most of the market share. The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, is driving the need for CDSS to assist healthcare providers in managing complex patient cases.

The growth of telehealth and remote patient monitoring is creating opportunities for CDSS to support virtual consultations, remote diagnostics, and continuous health data tracking, especially in underserved regions. Improvements in healthcare infrastructure, along with the increasing adoption of electronic health records (EHRs) in hospitals and clinics, are facilitating the integration of CDSS into clinical workflows.

Increased investments in the healthcare sector across countries like Australia, China, India, and Japan are boosting the CDSS market. Governments in key economies are increasing research and development (R&D) expenditures to promote greater integration of information technology within the medical field. Governments in the region are actively supporting the adoption of HCIT solutions through various initiatives, which, along with rising healthcare expenditure and the presence of skilled IT professionals, support market growth36.

Technological advancements, notably the integration of AI and machine learning, are revolutionizing the Asia-Pacific CDSS market by enhancing patient data analysis and enabling more personalized treatment approaches. For instance, in January 2025, Agilus Diagnostics, India's largest diagnostic network, achieved a breakthrough in genomic testing by offering a 3-day turnaround time (TAT) for myeloid malignancy test results5. This advancement addresses a crucial need in precision oncology, significantly reducing the typical two-to-three-week wait for results and enabling faster clinical decisions for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN).

Also, In June 2024, DocMode introduced AIDE (Assistant for Improved Decision-making with Evidence), an AI-driven clinical decision support system (CDSS) designed to assist healthcare professionals in enhancing their clinical decision-making processes. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global clinical decision support system market.

Competitive Landscape

The major global players in the clinical decision support system market include Wolters Kluwer, Oracle (Cerner Corporation), Epic Systems Corporation., McKesson Corporation, Veradigm Inc. (Allscripts Healthcare, LLC), Elsevier, Optum, Inc., Siemens Healthcare Private Limited, Zynx Health, Inc., and Merative among others.

Key Developments

  • In January 2025, the Food and Drug Administration (FDA) issued draft guidance entitled "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products". This guidance provides recommendations on the use of AI intended to support regulatory decisions regarding the safety, effectiveness, and quality of drugs and biological products. It is the first guidance the agency has issued on the use of AI for the development of drug and biological products.
  • In January 2023, Signal 1, a health AI startup, launched its AI-powered clinical decision support system at Grand River Hospital. This deployment extends Signal 1's reach to benefit more people in Ontario1. The launch follows a collaboration between Signal 1 and Grand River Hospital clinical teams to adapt the system to the hospital's patient population and clinical routines.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global clinical decision support system market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Type
  • 3.3. Snippet by Component
  • 3.4. Snippet by Delivery Mode
  • 3.5. Snippet by Model
  • 3.6. Snippet by Mode of Advice
  • 3.7. Snippet by Application
  • 3.8. Snippet by End-User
  • 3.9. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Data Security and Privacy Concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest largest-selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Integrated CDSS*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Standalone CDSS

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Therapeutic CDSS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Diagnostic CDSS

8. By Component

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 8.1.2. Market Attractiveness Index, By Component
  • 8.2. Services*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Software
  • 8.4. Hardware

9. By Delivery Mode

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
  • 9.2. Market Attractiveness Index, By Delivery Mode
  • 9.3. Hospitals & Specialty Clinics*
    • 9.3.1. Introduction
    • 9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.4. Home Care Settings
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. On-Premise*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Web Based
  • 10.4. Cloud-Based

11. By Model

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 11.1.2. Market Attractiveness Index, By Model
  • 11.2. Knowledge-based CDSS*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Non-Knowledge-based CDSS

12. By Mode of Advice

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 12.1.2. Market Attractiveness Index, By Mode of Advice
  • 12.2. Active CDSS*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Passive CDSS

13. By Application

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.1.2. Market Attractiveness Index, By Application
  • 13.2. Drug-Drug Interaction*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Drug Allergy
  • 13.4. Clinical Reminders
  • 13.5. Clinical Guidelines
  • 13.6. Drug Dosing Support
  • 13.7. Others

14. By End-User

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 14.1.2. Market Attractiveness Index, By End-User
  • 14.2. Hospitals*
    • 14.2.1. Introduction
    • 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 14.3. Specialty Clinics
  • 14.4. Ambulatory Surgical Centers

15. By Region

  • 15.1. Introduction
    • 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 15.1.2. Market Attractiveness Index, By Region
  • 15.2. North America
    • 15.2.1. Introduction
    • 15.2.2. Key Region-Specific Dynamics
    • 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 15.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 15.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 15.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.2.11.1. U.S.
      • 15.2.11.2. Canada
      • 15.2.11.3. Mexico
  • 15.3. Europe
    • 15.3.1. Introduction
    • 15.3.2. Key Region-Specific Dynamics
    • 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 15.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 15.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 15.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.3.11.1. Germany
      • 15.3.11.2. U.K.
      • 15.3.11.3. France
      • 15.3.11.4. Spain
      • 15.3.11.5. Italy
      • 15.3.11.6. Rest of Europe
  • 15.4. South America
    • 15.4.1. Introduction
    • 15.4.2. Key Region-Specific Dynamics
    • 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 15.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 15.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 15.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.4.11.1. Brazil
      • 15.4.11.2. Argentina
      • 15.4.11.3. Rest of South America
  • 15.5. Asia-Pacific
    • 15.5.1. Introduction
    • 15.5.2. Key Region-Specific Dynamics
    • 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 15.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 15.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 15.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.5.11.1. China
      • 15.5.11.2. India
      • 15.5.11.3. Japan
      • 15.5.11.4. South Korea
      • 15.5.11.5. Rest of Asia-Pacific
  • 15.6. Middle East and Africa
    • 15.6.1. Introduction
    • 15.6.2. Key Region-Specific Dynamics
    • 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Delivery Mode
    • 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
    • 15.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Advice
    • 15.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 15.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

16. Competitive Landscape

  • 16.1. Competitive Scenario
  • 16.2. Market Positioning/Share Analysis
  • 16.3. Mergers and Acquisitions Analysis

17. Company Profiles

  • 17.1. Wolters Kluwer *
    • 17.1.1. Company Overview
    • 17.1.2. Product Portfolio
      • 17.1.2.1. Product Description
      • 17.1.2.2. Product Key Performance Indicators (KPIs)
      • 17.1.2.3. Historic and Forecasted Product Sales
      • 17.1.2.4. Product Sales Volume
    • 17.1.3. Financial Overview
      • 17.1.3.1. Company Revenue's
      • 17.1.3.2. Geographical Revenue Shares
      • 17.1.3.3. Revenue Forecasts
    • 17.1.4. Key Developments
      • 17.1.4.1. Mergers & Acquisitions
      • 17.1.4.2. Key Product Development Activities
      • 17.1.4.3. Regulatory Approvals etc.
    • 17.1.5. SWOT Analysis
  • 17.2. Oracle (Cerner Corporation)
  • 17.3. Epic Systems Corporation.
  • 17.4. McKesson Corporation
  • 17.5. Veradigm Inc. (Allscripts Healthcare, LLC)
  • 17.6. Elsevier
  • 17.7. Optum, Inc
  • 17.8. Siemens Healthcare Private Limited
  • 17.9. Zynx Health, Inc.
  • 17.10. Merative

LIST NOT EXHAUSTIVE

18. Appendix

  • 18.1. About Us and Services
  • 18.2. Contact Us